SARS-CoV-2 seroprevalence and characteristics of post-infection immunity in a general population cohort study in Catalonia, Spain.

Marianna Karachaliou (marianna.karachaliou@isglobal.org)  
Barcelona Institute for Global Health

Gemma Moncunill  
Barcelona Institute for Global Health

Ana Espinosa  
Barcelona Institute for Global Health

Gemma Castaño-Vinyals  
Barcelona Institute for Global Health

Alfons Jiménez  
Barcelona Institute for Global Health

Marta Vidal  
Barcelona Institute for Global Health

Rebeca Santano  
Barcelona Institute for Global Health

Diana Barrios  
Barcelona Institute for Global Health

Laura Puyol  
Barcelona Institute for Global Health

Anna Carreras  
Genomes for Life-GCAT lab. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

Leonie Mayer  
Barcelona Institute for Global Health

Rocío Rubio  
Barcelona Institute for Global Health

Beatriz Cortés  
Genomes for Life-GCAT lab. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

Vanessa Pleguezuelos  
Banc de Sang i Teixits

Cristina O’Callaghan-Gordo  
Barcelona Institute for Global Health

Serena Fossati  
Barcelona Institute for Global Health

Ioar Rivas  
Barcelona Institute for Global Health

Delphine Casabonne
Abstract

Sparse data exist on the complex natural immunity to SARS-CoV-2 at the population level. We applied a well-validated multiplex serology test in 5000 participants of a general population study in Catalonia in blood samples collected from end June to mid November 2020. Based on responses to fifteen isotype-antigen combinations, we detected a seroprevalence of 18.1% in adults (n=4740), and modeled extrapolation to the general population of Catalonia indicated a 15.3% seroprevalence. Antibodies persisted up to 9 months after infection. Immune profiling of infected individuals revealed that with increasing severity of infection (asymptomatic, 1-3 symptoms, ≥ 4 symptoms, admitted to hospital/ICU), seroresponses were more robust and rich with a shift towards IgG over IgA and anti-spike over anti-nucleocapsid responses. Among seropositive participants, lower antibody levels were observed for those ≥60 years old and smokers vs non-smokers. Overweight/obese participants vs normal weight had higher antibody levels. Adolescents (13-15 years old) (n=260) showed a seroprevalence of 11.5%, were less likely to be tested seropositive compared to their parents and had dominant anti-spike rather than anti-nucleocapside IgG responses. Our study provides an unbiased estimate of SARS-CoV-2 seroprevalence in Catalonia and new evidence on the durability and heterogeneity of post-infection immunity.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surveillance based on diagnostic testing, incomplete screening of all possible infections and imperfect test sensitivity may lead to a domino-like effect resulting in significant underestimation of the number of coronavirus disease 2019 (COVID-19) cases [1]. Several barriers, such as access to health-care, social stigma and financial worries if tested positive, may increase the magnitude of this underestimation. The high proportion of asymptomatic cases distorts even more the picture of the pandemic [2].

Seroepidemiological studies detect people who have had prior exposure to a pathogen and have developed antibodies and can provide us a better estimate of the proportion of the population infected. The majority of individuals infected with SARS-CoV-2 develop specific antibodies, but there are several challenges for serological surveys [3]. First, the virus has several antigenic epitopes that are the target of antibodies but not everyone responds to the same antigens [4]. Additionally, detection of certain isotype responses depends on the time since infection [5–7]. Within days of symptom onset, specific immunoglobulins M (IgM) are detected and after a lag period strong immunoglobulins G (IgG) responses typically occur. Immunoglobulin A (IgA) responses are detected almost concurrently to IgM or earlier. With time, attenuation of antibody levels is expected due to decay of immune responses and transition of immunoglobulin production from short to long-lived plasma cell; thus cut-offs for seropositivity should take into account levels of waning immunity [8, 9]. Moreover, the magnitude and type of antibody response correlates with disease severity. For example, most studies show that seroresponses are higher in more severe cases [10][11]. Nonetheless, most sero-epidemiological studies published up to date have been mainly geared toward studying IgG responses to only one antigen [12].

Limited data exist on the trajectories of immune responses to SARS-CoV-2 over time and the factors that determine their heterogeneity. Notably, most studies consider individuals hospitalized or at least requiring some outpatient treatment [7, 13–18]. Describing the characteristics of an effective immune response, as such encountered by asymptomatics or those with mild infections, is valuable. Early data show that some antigen and/or isotype responses dominate among milder infections [6, 18, 19]. Children are also facing effectively the infection, and studies comparing immune responses between SARS-CoV-2 infected children and adults have already provided some insights [20, 21]. Considering members of the same family may resolve further questions related to time of infection, genetics, and other shared environmental exposures.
Taking advantage of multiplex serology to SARS-CoV-2, we describe the sero-epidemiology in a population of 13–93 years old participants of existing cohort studies in Catalonia up to mid-November 2020. Catalonia in northeast Spain, has been among the hardest-hit populations in Europe from COVID-19.

**Results**

**SARS-CoV-2 seroprevalence**

Among the 10,837 adult participants of the COVID-19 Cohorts in CATalonia (COVICAT) study, the 4,740 (44%) who donated a blood sample for serological testing were more likely to report symptoms, not having been tested before, of higher education and less likely to work in their usual workplace and be smokers compared to those who participated only with questionnaire data (Supplementary Resource 1). A blood sample was available for all adolescents.

Table 1 presents the seroprevalence of SARS-CoV-2 based on the serostatus of fifteen isotype-antigen combinations [three isotypes: IgM, IgA and IgG; five viral target antigens: spike full protein (S), S2 fragment (S2), receptor binding domain (RBD), nucleocapsid full protein (NFL) and nucleocapsid C-terminal region (NCt)]. Details on the contribution of each isotype-antigen combination in the overall serostatus are available in Supplementary resource 2. The overall seroprevalence of SARS-CoV-2 among adults was 18.1% (IgM 3.7%, IgA 14.6%, IgG 9.0%) while 11.6% had an undetermined status. The highest prevalences were observed for RBD IgG (8.0%), S IgG (7.4%), RBD IgA (7.1%) and S IgA (6.9%). Adult participants of the second sampling period (n=1089, 23%) (median date: 30 October 2020, range 8 September-17 November 2020) were more likely to be seropositive compared to those of the first sampling period (median date: 19 July 2020, range 23 June-31 July 2020) (23.8% versus 16.4%) (Supplementary resource 3). To extrapolate the study results to Catalonia's adult population, we used raked weights to balance the study sample characteristics (age, sex, educational level, health region, smoking) to those of the total population (more details in methods). We estimated a seroprevalence of 15.3% in adults in Catalonia. Among the 260 adolescents (13-15 years old), 11.5% were seropositive and 7.3% had an undetermined status (Table 1).
le 1. SARS-CoV-2 seroprevalence (overall, by isotype, by isotype-antigen combination) in adult and adolescent participants of COVICAT study in Catalonia (sampling period: end June to mid November 2020).

|               | Adults (n=4740) |                      | Adolescents (n=260) |                      |
|---------------|----------------|----------------------|---------------------|----------------------|
|               | positive | negative | undetermined | positive | negative | undetermined |
| n             | n        | %        | n        | n        | %        | n        | n        | %        |
| **Overall**   |          |          |          |          |          |          |          |          |
| n             | 858      | 18.1     | 3331     | 70.3     | 551      | 11.6     | 30       | 11.5     | 211      | 81.2     | 19       | 7.3     |
| **Isotype**   |          |          |          |          |          |          |          |          |          |          |          |          |
| M             | 175      | 3.7      | 4392     | 92.7     | 173      | 3.6      | 3        | 1.2      | 250      | 96.2     | 7        | 2.7     |
| S             | 426      | 9.0      | 4134     | 87.2     | 180      | 3.8      | 24       | 9.2      | 225      | 86.5     | 11       | 4.2     |
| **Isotype-antigen combination** |          |          |          |          |          |          |          |          |          |          |          |          |
| M NFL         | 6        | 0.1      | 4694     | 99.0     | 40       | 0.8      | 0        | 0        | 260      | 100      | 0        | 0.0     |
| M NCt         | 18       | 0.4      | 4674     | 98.6     | 48       | 1.0      | 0        | 0        | 258      | 99.2     | 2        | 0.8     |
| M RBD         | 88       | 1.9      | 4552     | 96.0     | 100      | 2.1      | 1        | 0.4      | 253      | 97.3     | 6        | 2.3     |
| M S           | 49       | 1.0      | 4601     | 97.1     | 90       | 1.9      | 0        | 0        | 259      | 99.6     | 1        | 0.4     |
| M S2          | 20       | 0.4      | 4637     | 97.8     | 83       | 1.8      | 0        | 0        | 258      | 99.2     | 2        | 0.8     |
| NFL           | 140      | 3.0      | 4310     | 90.9     | 290      | 6.1      | 1        | 0.4      | 256      | 98.5     | 3        | 1.2     |
| NCt           | 129      | 2.7      | 4479     | 94.5     | 132      | 2.8      | 0        | 0        | 257      | 98.8     | 3        | 1.2     |
| RBD           | 338      | 7.1      | 4210     | 88.8     | 192      | 4.1      | 17       | 6.5      | 240      | 92.3     | 3        | 1.2     |
| S             | 325      | 6.9      | 4259     | 89.9     | 156      | 3.3      | 13       | 5.0      | 245      | 94.2     | 2        | 0.8     |
| S2            | 209      | 4.4      | 4201     | 88.6     | 330      | 7.0      | 4        | 1.5      | 255      | 98.1     | 1        | 0.4     |
| NFL           | 59       | 1.2      | 4473     | 94.4     | 208      | 4.4      | 2        | 0.8      | 246      | 94.6     | 12       | 4.6     |
| NCt           | 98       | 2.1      | 4481     | 94.5     | 161      | 3.4      | 5        | 1.9      | 245      | 94.2     | 10       | 3.8     |
| RBD           | 380      | 8.0      | 4308     | 90.9     | 52       | 1.1      | 21       | 8.1      | 237      | 91.2     | 2        | 0.8     |
| S             | 351      | 7.4      | 4307     | 90.9     | 82       | 1.7      | 21       | 8.1      | 233      | 89.6     | 6        | 2.3     |
| S2            | 104      | 2.2      | 4353     | 91.8     | 283      | 6.0      | 6        | 2.3      | 233      | 89.6     | 21       | 8.1     |

**Antibody levels in time since infection**

We examined the association of time since infection with antibody levels using cross-sectional data from all seropositive adults with an estimated time since infection ranging from 23-273 days (Figure 1). For each isotype-antigen combination, levels are plotted irrespective of the serostatus to the specific combination to not affect the heterogeneity of responses expected with time. We observed that RBD, S, and S2 IgM levels decreased significantly over time, with NFL and NCt IgMs being less affected but very few participants were actually seropositive to the specific isotype-antigen combinations. IgA responses to NFL, NCt and RBD sustained in time but those of IgA to S and S2 declined after around 120 days to lower levels. IgG responses seemed to be stable or peaking around 100 days
after infection and then started to decline rapidly for NFL IgG, modestly for RBD and S IgG, while NCt and S2 IgG levels were minimally affected. In a subgroup of 99 participants who were previously tested positive (self-reported result), 92% had a positive multiplex serology at a median of 102 days after first diagnosis (range: 13-233 days) (Supplementary resource 4).

**SARS-CoV-2 serology by COVID-19 symptoms**

We present the distribution of symptoms among adults and adolescents by SARS-CoV-2 serostatus in Table 2. Among adults, all symptoms were more prevalent (p-value<0.05) in SARS-CoV-2 seropositive versus seronegative participants with most remarkable differences seen for loss of odor/taste and fever. Among seropositives, 38.4% were asymptomatic and seropositives versus seronegatives were more likely to report ≥4 symptoms (28.5% vs 9.6%). The distribution of symptoms among seropositive adolescents was slightly different compared to adults, with a statistically significant higher proportion reporting chest pain (25% vs. 8% in adolescents and adults respectively), and a lower proportion reporting fever (16.7% vs. 30.6%) and respiratory symptoms (cough & dyspnea 25% vs. 39.1%). Having four or more symptoms, fatigue, chest pain, runny nose, loss of odor/taste and fever were statistically significant more prevalent in seropositive versus seronegative adolescents.
Table 2. Symptoms prevalence (%) by SARS-CoV-2 serostatus in adult and adolescent participants of the COVICAT study in Catalonia.

| Symptoms          | Adults          | Adolescents     |
|-------------------|-----------------|-----------------|
|                   | seropositive    | seronegative or undetermined | seropositive | seronegative or undetermined |
| Headache          | 35.1            | 23.4            | Fatigue      | 37.5            | 17.3            |
| Muscle/joint pain | 35.0            | 17.7            | Headache     | 33.3            | 26.2            |
| Fever             | 30.6            | 9.4             | Muscle/joint pain | 29.2            | 14.9            |
| Fatigue           | 30.5            | 15.0            | Chest pain   | 25.0            | 6.0             |
| Cough             | 27.0            | 13.9            | Runny nose   | 25.0            | 10.7            |
| Loss of odor/taste| 22.2            | 1.6             | Loss odor/taste | 25.0            | 1.2             |
| Runny nose        | 17.5            | 14.6            | Nausea/vomiting | 20.8            | 6.5             |
| Diarrhea          | 17.5            | 10.2            | Diarrhea     | 16.7            | 7.7             |
| Dyspnea           | 12.1            | 5.7             | Fever        | 16.7            | 5.4             |
| Rash              | 8.6             | 4.2             | Cough        | 16.7            | 10.7            |
| Chest pain        | 8.0             | 5.1             | Dyspnea      | 8.3             | 5.4             |
| Nausea            | 5.8             | 3.0             | Rash         | 0               | 4.2             |

| Number of symptoms | Adults | Adolescents |
|---------------------|--------|-------------|
| 0 symptoms          | 38.4   | 54.6        |
| 1-3 symptoms        | 33.1   | 35.8        |
| ≥4 symptoms         | 28.5   | 9.6         |
| 0 symptoms          | 33.3   | 54.8        |
| 1-3 symptoms        | 29.2   | 35.7        |
| ≥4 symptoms         | 37.5   | 9.5         |

Symptoms are sorted in adults and adolescents in decreasing frequency as observed among seropositives.

Darker red = higher prevalence

**Demographic and clinical** characteristics of adult participants according to SARS-CoV-2 serostatus and severity of infection are presented in Supplementary Resource 5. Participants reporting contact with a COVID-19 case and non-smokers were more likely to be seropositive. The proportion of participants reporting contact with a COVID-19 case, being previously tested, with any chronic disease or being overweight/obese increased with the severity of infection.

**Antibody responses by the severity of infection**

To determine whether the severity of infection is associated with quantitatively and qualitatively different antibody responses we performed four analyses. Firstly, we compared antibody levels of the fifteen isotype-antigen combinations between asymptomatic individuals (n=322), those reporting 1-3 symptoms (n=276), those reporting ≥4 symptoms (n=216) and those admitted to hospital/ICU (n=24) (Figure 2a). We observed lower levels among
asymptomatics and higher levels among those admitted to hospital/ICU (apart from NFL and NCT IgMs). Gradient differences were most evident among IgG to NFL and NCT and all RBD, S and S2 responses. Secondly, we found that the breadth of positive immune responses (aggregate number of seropositive isotype-antigen combinations), increased with severity of infection (Figure 2b). Thirdly, we explored differences in isotype responses. We observed a higher increase in levels of IgG than IgA responses with increasing severity (Figure 2a). In Figure 2c, using IgA/IgG ratios, we observed that IgA levels were closer to IgG levels among asymptomatics and more likely to exceed them compared to those with more severe infection. Also, we found that among asymptomatics, a higher proportion (46%) had more positive IgA than IgG responses compared to the 13% displaying more IgG than IgA responses (Figure 2d). We observed reverse findings among those hospitalized. Finally, we compared responses related to spike protein versus nucleocapsid antigens. Experiencing a more severe infection was associated with a shift towards spike over nucleocapsid antibody responses (Figure 2e). The overall trend is reflected in the last graph of Figure 2e depicting differences in the number of features that had greater spike than nucleocapsid related responses (ratios over one). Because time since infection may impact the associations mentioned above, we repeated all analyses in two strata of seropositive individuals those sampled before and after 120 days since infection. Results were materially unchanged (data not shown).

**Antibody responses by age, sex, and lifestyle characteristics**

We examined differences in antibody levels and breadth of positive immune responses among seropositive adults with respect to age, sex, smoking, and body mass index (BMI) status before confinement (table 3 & supplementary resource 7). Participants 60 years of age or older had lower responses to almost all isotype-antigen combinations and a lower breadth of positive responses but had higher levels of NFL IgA. Females had statistically significant higher NFL, NCT and S2 IgM responses but lower NFL, NCT, and S2 IgA responses. Overweight or obese people had higher levels to almost all IgA and IgG responses and a higher breadth of positive responses. On the other hand, smokers displayed lower levels of almost all antibodies and a lower breadth of positive responses. We additionally adjusted for the severity of infection, considering it as a mediator of the associations. After adjustment, age >60 years old was associated with lower levels of IgM to S2 but higher levels of IgA to NFL. Associations with sex remained, with women showing an overall lower number of positive responses. Associations with overweight/obesity were largely diluted but remained positive. Smoking was consistently associated with lower levels and a lower breadth of positive responses. We repeated all the analyses excluding those seronegative for each isotype-antigen combination and results for smoking and BMI status were similar (supplementary resource 7).
Table 3. Adjusted associations ($\beta$) between each characteristic and antibody levels for each of the fifteen isotype-antigen combinations and the breadth of positive immune responses for SARS-CoV-2 seropositive participants, the COVICAT study

| Characteristic          | IgM NFL | IgM NCt | IgM RBD | IgM S | IgM S2 | IgA NFL | IgA NCt | IgA RBD | IgA S | IgA S2 | IgG NFL | IgG NCt | IgG RBD | IgG S | IgG S2 | breadth |
|-------------------------|---------|---------|---------|-------|--------|---------|---------|---------|-------|--------|---------|---------|---------|-------|--------|---------|
| ≥60 years old           | -0.02   | -0.03   | -0.1    | -0.08 | -0.14  | 0       | -0.07   | -0.09   | -0.15 | -0.04  | -0.11   | -0.18   | -0.17   | -0.15 | -0.45  |
| Female sex              | 0.15    | 0.12    | 0.02    | 0.02  | 0.07   | -0.07   | -0.06   | -0.03   | -0.04 | -0.11  | 0       | -0.05   | 0.01    | -0.01 | -0.18  |
| Obese/overweight        | -0.03   | 0.01    | 0.04    | 0.04  | 0      | 0.05    | 0.03    | 0.11    | 0.08  | 0.11   | 0.07    | 0.07    | 0.15    | 0.14 | 0.11   | 0.71    |
| Smoker                  | 0.03    | 0.02    | -0.05   | -0.09 | -0.09  | -0.07   | -0.04   | -0.1    | -0.16 | -0.16  | -0.22   | -0.21   | -0.35   | -0.38 | -0.3   | -1.13   |

Associations ($\beta$ coefficients) of each listed characteristic with log_{10} transformed MFI values of each isotype-antigen combination adjusted for all the listed characteristics and days since infection. Bold indicates statistically significant associations (Appendix 9 presents corresponding p-values and 95% CI). The red color indicates a positive association while the blue color a negative association (associations with breadth are not comparable with those of antibody levels and thus not colored).

Antibody responses among adolescents

Serological data among 260 parent-child pairs showed a much lower risk for seropositivity among adolescents (n=30) than their parents (n=50) [RR: 0.6, 95% CI: 0.39-0.91)]. Sample collection took place at the same day for parents and their children. Among seropositive, adolescents had higher responses to S, S2 and RBD IgG, whereas parents had higher responses to NFL and NCt IgA (supplementary Resource 8). The dominant IgG responses related to spike protein (S, S2, RBD) observed among adolescents were further confirmed when we compared the ratios of spike versus nucleocapsid responses (figure 3a) and the number of positive IgG compared to IgA or IgM (figure 3b). When we restricted our analysis to the 16 parent-child pairs that were both tested seropositive, we observed similar results although most were no longer statistically significant (data not shown).

Discussion

The COVICAT study is one of the largest studies examining the complex natural immunity to SARS-CoV-2 at a population level. Based on multiplex serology testing of 5000 participants, we detected a SARS-CoV-2 seroprevalence of 18.1% in adults and much lower, of 11.5%, in adolescents. Additionally, 11.6% of adults and 7.3% of adolescents showed marginal seroresponses (undetermined). Severity of infection, determined the magnitude, breadth and specificity (towards certain antigens and/or isotypes) of immune responses long time after the acute phase of
infection. We also identified diverse associations between individuals’ characteristics, including age, sex, smoking, and BMI status, with antibody responses.

Up to mid-November, there were 238,596 confirmed COVID-19 cases in Catalonia in people > 20 years old which corresponds to 3.9% of the population [22]. This proportion is much lower than our estimation of infected individuals based on serology (18.1%). We expected this difference, as surveillance systems are restricted by the emergency and load of testing clinically evident infections and high-risk individuals. Meanwhile, updated data from the fourth phase of a nationwide seroprevalence study in Spain (ENE-COVID) reported a seroprevalence of 9.9% in Spain and 11.6% in Catalonia until the end of November [23]. They used two tests, a point-of-care rapid test determining IgG against RBD and an immunoassay detecting IgG against nucleocapsid (not yet available for the fourth phase). Although the seroprevalence in ENE-COVID for Catalonia is lower than in our study it is not so different when compared with the seroprevalence for RBD and/or NCT IgG being 8.1% in our study. Thus, the difference in seroprevalence between the two studies could be partially attributable to the less extensive serological testing in ENE-COVID compared to our multiplex approach. Another argument for this scenario is that seroprevalence in adolescents, whose responses were primarily IgG anti-RBD, was not so different between the two studies (8.6% for 10–14 years of age in ENECOVID and 11.5% for 13–15 years old in our study). An increasing number of seroprevalence surveys now utilize multi-antigen and multi-isotype antibody responses because seroresponses might be skewed to different antigens and isotypes depending on clinical and individuals’ characteristics [14, 24, 25]. Also, the importance of IgA isotype in diagnostic accuracy of SARS-CoV-2 serological tests is emerging [5, 15, 26].

We found no differences in seroprevalence between females and males or with age among adults. Interestingly, seropositive participants older than 60 years of age had higher NFL IgA levels and women had lower antibody levels and number of seropositive responses (apart from NFL and NCT IgM). Age and sex-specific antibody responses against SARS-CoV-2 have been documented but results are mixed [14, 27, 28]. Similar to other studies, seroprevalence among young adolescents was lower than among adults [29]. Within one family, adolescents were at lower risk for seropositivity compared to their parents. We cannot make direct conclusions about children's role in transmitting SARS-CoV-2 within the household, but evidence argues for a reduced, marginal or conditional contribution [29, 30]. It remains unclear why children are less susceptible to infection but mechanisms related to the number of ACE-2 receptors [31], the naivety of innate immunity [32] and preexisting human coronaviruses-elicited immunity [33] are proposed.

A striking observation was that over 90% of previously tested positive participants had detectable antibodies up to 7 months after their first diagnosis, but most of them were either hospitalized or had experienced ≥ 4 symptoms. In the overall seropositive population of our study including infections of varying severity, we observed sustained levels for IgA and IgG responses at least 4 months after infection. More stable responses up to 9 months after infection were evident for NCT, RBD IgA and NCT, S2 IgG. We did not have repeated samples but a number of other studies did and showed limited loss of IgG antibodies and some loss of IgA antibodies over time [7, 14, 16, 34, 35]. More importantly, two recent studies showed that seropositive participants had a significantly decreased risk of re-infection up to 6 months after first infection [36, 37]. It remains to be determined what levels of antibodies to what specific antigen epitopes protect people from recurrent infections.

Our findings are in agreement with previous reports showing that asymptomatics account for a significant proportion of the infected population (approximately 40%) and that a range of symptoms occurs with COVID-19 infection with the most specific being the loss of odor/taste and fever [38, 39]. Importantly, the clinical spectrum of SARS-CoV-2 infection reflects the spectrum of immune responses. With increasing severity of infection, we observed that hosts mounted more robust and rich responses. A recent study showed that the immune response of severely infected
subjects was spread to subdominant viral antigens as well [40]. A novel finding in our study was that asymptomatics were more likely to have greater IgA than IgG responses compared to those experiencing more severe disease nonetheless the magnitude of IgA responses remained in lower levels in asymptomatics compared to those admitted to hospital/ICU. IgA could contribute to virus neutralization early in the infection to a greater extent compared with IgG [6]. Similar to us, most studies have described higher levels of antibodies among those with more severe disease, and some have suggested that a robust IgA response, in particular, may have a pathological role in SARS-CoV-2 infection [7, 14, 15, 21]. Collectively with our data, it seems that IgA at low levels may be able to control the infection, but it could be associated with detrimental effects when boosted to higher levels along with other responses. In our study, we cannot disentangle to which extent the severity of infection drives these immune responses or whether these responses play a role in the pathogenesis of SARS-CoV-2.

Contradictory to two previous smaller studies, we found a shift towards spike over nucleocapsid responses with increasing severity of infection [17, 18]. This discrepancy might be related to the fact that each study examined different immune features and we collected samples long after infection. Different rates of decay of anti-spike versus anti-nucleocapsid antibodies might have affected our results [41, 42]. Although unclear, it is possible that the severity of infection determines the antibody production in the longterm (e.g. from long-lived plasma cells) in an antigen-specific manner [43]. For example, a recent study demonstrated that subjects with more severe disease mounted a larger memory B cell formation against the spike, but not the nucleocapsid [40]. Serological data from the group of adolescents point to very specific responses mainly of IgG against spike protein, consistent with previous studies [20, 21]. We should note that children until late adolescence have a lower capacity of generating IgA [44]. These data suggest that adolescents use IgG alone to control the infection and that lack of anti-nucleocapsid responses might indicate a less widespread infection than adults. Such differences between adult and childhood immune responses should be delineated given the less harmful effects of SARS-CoV-2 infection in children.

Consistent with other studies, we detected higher levels of antibodies among overweight/obese participants. This association largely diluted when we adjusted for severity of infection, suggesting that higher levels were a consequence of the more severe disease experienced by obese people (adjustment by severity of infection not considered in previous studies) [14, 45]. In our population, the highest proportion of overweight/obese people was among those experiencing more severe infection. World Obesity Forum recently reported that COVID-19 mortality increased along with the countries' prevalence of obesity, even after adjusting for age and wealth [46]. These data suggest that despite displaying robust serological responses, overweight/obese infected people are more likely to develop severe infection than non-overweight/obese people. Reduced levels of SARS-CoV-2 antibodies and breadth of immune responses were detected among seropositive smokers compared to non-smokers irrespective of the severity of infection. Two studies report similar results concerning levels of antibodies [14, 47]. These data suggest that smokers present a weakened immune response to SARS-CoV-2. Thus, the higher COVID-19 morbidity among smokers might be due to impaired immunity as reflected in lower antibody levels [48]. Simultaneously, the paradox of low prevalence of smoking among SARS-CoV-2 infected people might be due low/non-detectable levels of antibodies. Of course, this would not affect results relevant to PCR but it has been suggested, although not investigated, that smoking might decrease nasopharyngeal viral load resulting more often in false-negative results [49]. We need more studies in this perspective.

We acknowledge that this is not a random population-based study as it recruited participants from pre-existing cohorts. On the other hand, existing cohorts allow us to quickly contact a population, achieve a high participation rate and access pre-pandemic information. The study primarily consisted of people 40–70 years old (≈ 90%), owing to the age distribution in original cohorts but we combined several cohorts in order to include younger and older people. Volunteer bias is always of concern, as we observed a lower participation rate for those who had received a test; this
would have lead to underestimation of true seroprevalence. We assumed that all persons infected with SARS-CoV-2 have detectable antibodies at the time of sampling. The 8% of previously tested positive participants with a negative serology in our study might indicate the proportion of the population who lost immunity, were antibody non-responders or false-positive results in the first test. Moreover, we could not verify whether the symptoms reported were attributable to a SARS-CoV-2 infection given the limited access of the population to diagnostic tests at the initial months of the pandemic.

**Conclusion**

Collectively, the data presented here argue for a higher number of exposed individuals to SARS-CoV-2 in Catalonia, than what had been described, but still the majority of the population remains unexposed. Although further analysis with repeated samples will allow us to describe the progression of antibody levels in time, we observed that even 4–9 months after infection, responses against SARS-CoV-2 were evident. Individuals presented strikingly different immune responses depending on the severity of infection. Factors such as obesity and smoking that are related to significant COVID-19 morbidity and mortality probably determine immune responses.

**Methods**

**Study design and setting**

The COVICAT study includes participants from different pre-existing ongoing population-based cohorts in Catalonia and was developed following the COVID-19 pandemic. Eligible participants were from three adult population-based cohorts (GCAT, Genomes for life [50]; MCC-Spain, population controls from Catalunya [51]; and ECRHS, European Community Respiratory Health Survey [52]), two mother-child cohorts [INMA-Sabadell, (INfancia y Medio Ambiente) [53] children born in 2005-2007 and their mothers; BiSC, Barcelona Life Study Cohort pregnant women recruited immediately before and during the pandemic] and two small general population cohorts in special populations (Urban Training, older persons; and LeRAsgs, rural population). The eligible adult population consists of 19,424 people and we were able to contact 18,737 (96%) using email and telephone messages or calls. Of them, 10,837 (58%) participated in the study. Just after the strict first confinement period, we invited them to complete an online questionnaire about COVID-19 compatible symptoms, diagnostics as well as about occupational and financial aspects, sociodemographic and lifestyle characteristics, mental health and chronic diseases. We also did telephone interviews for those unfamiliar with the use of online approaches. Participants were then asked to donate a blood sample in different facilities. We offered the option for older people and those living in remote areas of collecting a blood fingerprick sample at their residence, as well as a second opportunity for donating a blood sample during September-November 2020 for all participants not able to provide a sample earlier. Participants of the second sampling period completed an additional questionnaire related to COVID-19 symptoms and testing in order to update the relative information from the main questionnaire. We also had available samples and questionnaire information on 260 adolescent participants of the INMA-Sabadell, cohort. Details on the sources and methods of assessment of variables are presented in the Supplementary resource 9.

All participants gave written informed consent before participation in the study. For individuals younger than 18 years, parents or a legal representative provided consent. The study was approved by the Parc de Salut Mar Drug Research Ethical Committee (IBR number: 2020/9307/I). All methods were performed in accordance with the relevant guidelines and regulations.

**Serology**
Blood samples were processed within 24 hours of collection and were analyzed at the ISGlobal Immunology laboratory in Barcelona. The levels [median fluorescence intensity (MFI)] of IgG, IgM and IgA were assessed by high-throughput multiplex quantitative suspension array technology, including, as SARS-CoV-2 antigens, the S (aa 1-1213 expressed in Expi293 and His tag-purified) and the S2 fragment (purchased from SinoBiologicals), the RBD (donated by the Krammer lab, Mount Sinai, NY), the NFL and the specific NCoV (expressed in E. coli and His tag-purified). Assay performance was previously established as 100% specificity and 95.78% sensitivity for seropositivity 14 days after symptoms onset [54]. Antigen-coupled microspheres were added to a 384-well μClear® flat bottom plate (Greiner Bio-One, Frickenhausen, Germany) in multiplex (2000 microspheres per analyte per well) in a volume of 90 μL of Luminex Buffer (1% BSA, 0.05% Tween 20, 0.05% sodium azide in PBS) using 384 channels Integra Viaflo semi-automatic device (96/384, 384 channel pipette). Hyperimmune pools were used as positive controls prepared at 2-fold, 8 serial dilutions from 1:12.5. Pre-pandemic samples were used as negative controls to estimate the cut-off of seropositivity.

Ten μL of each dilution of the positive control, negative controls and test samples (prediluted 1:50 in 96 round-bottom well plates), were added to a 384-well plate using Assist Plus Integra device with 12 channels Voyager pipette (final test sample dilution of 1:500). To quantify IgM, test samples and controls were pre-treated with anti-Human IgG (Gullsorb) at 1:10 dilution, to avoid IgG interferences. Technical blanks consisting of Luminex Buffer and microspheres without samples were added in 4 wells to control for non-specific signals. Plates were incubated for 1 h at room temperature in agitation (Titramax 1000) at 900 rpm and protected from light. Then, the plates were washed three times with 200 μL/well of PBS-T (0.05% Tween 20 in PBS), using BioTek 405 TS (384-well format). Twenty five μL of goat anti-human IgG-phycocerythrin (PE) (GTIG-001, Moss Bio) diluted 1:400, goat anti-human IgA-PE (GTIA-001, Moss Bio) 1:200, or goat anti-human IgM-PE (GTIM-001, Moss Bio) 1:200 in Luminex buffer were added to each well and incubated for 30 min. Plates were washed and microspheres resuspended with 80 μL of Luminex Buffer, covered with an adhesive film and sonicated 20 seconds on sonicator bath platform, before acquisition on the Flexmap 3D reader. At least 50 microspheres per analyte per well were acquired, and MFI was reported for each analyte. Assay positivity cut-offs specific for each isotype and analyte were calculated as 10 to the mean plus 3 standard deviations of log_{10} transformed MFI of 128 pre-pandemic controls. Results were defined as undetermined when the MFI levels for a given isotype-analyte were between the positivity threshold and an upper limit at 10 to the mean plus 4.5 standard deviations of the log_{10} transformed MFIs of pre-pandemic samples, and no other isotype-antigen combination was above the positivity cut-off.

Statistics

Descriptive analyses of the study population characteristics were conducted. We used raked weights to extrapolate seroprevalence to the total population of Catalonia aged more than 20 years. Briefly, raking calculates weights so that the weighted sample has the same marginal distribution than the reference population in terms of the variables used to calculate the weights [55]. In particular, we used the joint sex-age (in 10-year groups) distribution, educational level, health region and smoking. Population data were obtained from the National Statistics Institute and from the Catalan Health Survey[56]. The COVICAT study includes lower numbers of younger ages, which leads to overdispersed weights and gaps in the distribution of the weights. For this reason, we restricted the extremes weights by trimming the distribution at 99% of the weights. Generalized additive models were used to explore the shape of the relationship between days since infection and antibody levels to each of the fifteen isotype-antigen combination. Antibody levels were log_{10} transformed to normalise their distribution. Differences in antibody levels and ratios by severity of infection were examined using oneway Anova and pairwise comparisons were performed using Tukey post hoc-test. Differences in immune responses between adolescents and parents were examined with t-tests. Multivariable regression models were applied to examine among seropositive individuals the association between age, sex, smoking and BMI status before confinement (all in the same model adjusted also for days since infection) and log_{10}
transformed antibody levels and the breadth of positive responses. All analyses were conducted using Stata version 16 (StataCorp LP, College Station, Texas).

References

1. Alwan NA. Surveillance is underestimating the burden of the COVID-19 pandemic. The Lancet. 2020;396:e24.
2. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. Serra R, editor. PLOS ONE. 2020;15:e0241536.
3. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. Emerg Infect Dis. 2020;26:1978–86.
4. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21:73–82.
5. Vogl T, Leviatan S, Segal E. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. Cell Rep Med. 2021;2:100191.
6. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13.
7. Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56:2001526.
8. Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe. 2020;S2666652472030197X.
9. Alter G, Seder R. The Power of Antibody-Based Surveillance. N Engl J Med. 2020;383:1782–4.
10. van Tol S, Mögling R, Li W, Godeke G-J, Swart A, Bergmans B, et al. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. Emerg Microbes Infect. 2020;9:1965–73.
11. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4.
12. Lai C-C, Wang J-H, Hsueh P-R. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314–22.
13. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. Mantis NJ, editor. PLOS ONE. 2020;15:e0244126.
14. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:1724–34.
15. Grossberg AN, Koza LA, Ledreux A, Prusmack C, Krishnamurthy HK, Jayaraman V, et al. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nat Commun. 2021;12:740.
16. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.
17. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5.
18. Atyeo C, Fischinger S, Zohar T, Stein MD, Burke J, Loos C, et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity. 2020;53:524–532.e4.
19. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5:eabe0240.

20. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin W-H, Wontakal S, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22:25–31.

21. Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021;

22. https://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus.

23. Estudio ENE-COVID: cuarta ronda estudio nacional de sero-epidemiologia de la infeccion por SARS-CoV-2 en Espanya. 2020.

24. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.

25. Knabl L, Mitra T, Kimpel J, Rössler A, Volland A, Walser A, et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl [Internet]. Epidemiology; 2020 Aug. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.08.20.20178533

26. Burgess S, Ponsford MJ, Gill D. Are we underestimating seroprevalence of SARS-CoV-2? BMJ. 2020;m3364.

27. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34:339–43.

28. Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N, et al. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl Res J Lab Clin Med. 2021;

29. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2021;175:143.

30. Li F, Li Y-Y, Liu M-J, Fang L-Q, Dean NE, Wong GWK, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021;S1473309920309816.

31. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA. 2020;323:2427.

32. Carsetti R, Quintarelli C, Quinti I, Piano Mortari E, Zumla A, Ippolito G, et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? Lancet Child Adolesc Health. 2020;4:414–6.

33. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339–43.

34. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature [Internet]. 2021 [cited 2021 Mar 14]; Available from: http://www.nature.com/articles/s41586-021-03207-w

35. Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M, et al. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. J Infect Dis. 2021;223:62–71.

36. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. JAMA Intern Med [Internet]. 2021 [cited 2021 Mar 14]; Available from:
37. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2021;384:533–40.

38. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. Ann Intern Med. 2021;

39. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 2021 [cited 2021 Mar 15]; Available from: http://doi.wiley.com/10.1002/14651858.CD013665.pub2

40. Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, et al. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. Schultz-Cherry S, editor. mBio. 2021;12:e02940-20, /mbio/12/1/mBio.02940-20.atom.

41. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Subbarao K, editor. J Virol. 2020;95:e01828-20, /jvi/95/3/JVI.01828-20.atom.

42. Manisty C, Treibel TA, Jensen M, Semper A, Joy G, Gupta RK, et al. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS–CoV-2 infection. EBioMedicine. 2021;65:103259.

43. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. 2020;20:229–38.

44. Buckley RH, Dees SC, O’Fallon WM. Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy. Pediatrics. 1968;41:600–11.

45. Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, et al. Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. J Clin Endocrinol Metab. 2021;dgab004.

46. World Obesity Foundation. COVID-19 and Obesity: The 2021 Atlas. 2021.

47. Schaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL, et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J Clin Med. 2020;9:3989.

48. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PloS One. 2020;15:e0233147.

49. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20:1034–42.

50. Obón-Santacana M, Vilardell M, Carreras A, Duran X, Velasco J, Galván-Femenía I, et al. GCAT|Genomes for life: a prospective cohort study of the genomes of Catalonia. BMJ Open. 2018;8:e018324.

51. Castaño-Vinyals G, Aragonés N, Pérez-Gómez B, Martín V, Llorca J, Moreno V, et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gac Sanit. 2015;29:308–15.

52. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. Eur Respir J. 1994;7:954–60.
53. Guxens M, Ballester F, Espada M, Fernández MF, Grimalt JO, Ibarluzea J, et al. Cohort Profile: the INMA–INfancia y Medio Ambiente–(Environment and Childhood) Project. Int J Epidemiol. 2012;41:930–40.

54. Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. J Clin Microbiol. 2021;59.

55. Dal Grande E, Chittleborough CR, Campostrini S, Tucker G, Taylor AW. Health Estimates Using Survey Raked-Weighting Techniques in an Australian Population Health Surveillance System. Am J Epidemiol. 2015;182:544–56.

56. Garcia-Codina O, Juvinyà-Canal D, Amil-Bujan P, Bertran-Noguer C, González-Mestre MA, Masachs-Fatjo E, et al. Determinants of health literacy in the general population: results of the Catalan health survey. BMC Public Health. 2019;19:1122.

Declarations

Funding: This work was funded by Incentius a l’Avaluació de Centres CERCA (in_CERCA); EIT HEALTH BP2020-20873-Certify.Health.; Fundació Privada Daniel Bravo Andreu; PID2019-110810RB-I00 grant (Spanish Ministry of Science & Innovation). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S). ISGlobal and IGTP receive support from the Generalitat de Catalunya through the CERCA Program. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Acknowledgments: We thank the volunteers who participate in the cohort studies, all the workers in different facilities of the Blood and Tissue Bank for sample recruitment, Jordi Chi for antigen expression and purification and Victor Moreno for data collection in MCC study. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundacio IGTP. IGTP is part of the CERCA Program / Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat de Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). Full list of the investigators who contributed to the generation of the GCAT data is available from www.genomesforlife.com. LeRAgs is supported by Instituto de Salud Carlos III (PI17/01555). Beatriz Cortés is supported by ISCIII national grant PI18/01512. Ioar Rivas is supported from the postdoctoral fellowships programme Beatriu de Pinós (2018 BP 00114), funded by the Secretary of Universities and Research (Government of Catalonia) and by the Horizon 2020 programme of research and innovation of the European Union under the Marie Sklodowska-Curie grant agreement No 801370.

Conflicts of interest: The authors declare that they have no conflict of interest.

Authors’ contributions: Conceptualization: MKar, GM, CD, MKog; Methodology: MKar, GM, CD, DB, LP, RA, LM, RR, LI, LM, RR, LI, VP; Formal analysis: MKar, AE, XB; Investigation: AJ, MV, RS, DB, LP, RA, LM, RR, LI, VP, SF, IR; Data curation: AJ, MV, RS, DB, LP, RA, AC, BC, AE, GCV; Writing-original draft preparation: MKar, GM, CD, MKog; Writing-review and editing: MKar, GM, AE, GCV, AJ, MV, RS, DB, LP, AC, LM, RR, BC, VP, COG, SF, IR, DC, MV, LI, RA, XB, JGA, RdC, CD, MKog; Visualization: MKar, AE; Funding acquisition: GM, CD, MKog; Project administration: GCV; Supervision: GM, CD, MKog

Figures
Figure 1

Generalized additive models for associations (95% CIs) of days since infection with antibody responses to the fifteen isotype-antigen combinations in seropositive participants of the COVICAT study. Plus symbols (+) represent overall seropositive participants and with grey color are participants seronegative to the specific isotype-antigen combination. For each isotype-antigen combination, levels are plotted irrespective of the serostatus to the specific combination.
Figure 2

Differences in antibody responses according to the severity of infection among SARS-CoV-2 seropositive participants. Comparison of A) antibody levels (log10-transformed values) of the fifteen isotype-antigen combinations, B) breadth of positive immune responses ranging from 0 responses (light grey) to 13 responses (almost black), C) ratio IgA/IgG antibody levels (log10-transformed values) for each of the antigens (the proportion of the participants showing ratio>1 is listed in the top of each graph), D) proportion of people showing more IgA, more IgG and equal number of positive IgA and IgG responses and E) ratios of anti-spike (S, S2, RBD) over anti-nucleocapsid (NFL, Nct) responses for every combination and isotype. S for spike protein and N for nucleocapsid. Supplementary Resource 6 presents corresponding p-values.
Figure 3

Differences in antibody responses between SARS-CoV-2 seropositive adolescents and parents. Comparison of antibody responses, A) ratio of anti-spike (S, S2, RBD) over anti-nucleocapsid (NFL, NCt) responses for every combination and isotype and B) proportion of people showing more IgA or IgM, more IgG and equal number of positive IgA or IgM and IgG responses.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementary.docx